From Patent to Product: A Technical Gap Analysis and Redesign Framework Addressing the Murine CD40L Problem and Other Translational Vulnerabilities in CD40-Targeted Intranasal MERS-CoV Vaccine Development

This technical brief dissects US Patent 11,219,685, a CD40-targeted intranasal MERS-CoV vaccine and identifies critical translational vulnerabilities, including reliance on murine CD40L, narrow intranasal formulation constraints, consensus S1 antigen limitations, and Ad5 vector liabilities. Drawing on large-scale genomic surveillance and structural virology, our analysis reframes these gaps not as dead ends. This analysis does not assume whether the patent is intended for human or veterinary use; the key issue is the reliance on murine CD40L, creating a translational gap for any deployable product, but as actionable opportunities for de-risked, human-compatible redesigns with clear pathways to regulatory and commercial viability in the MENA region and beyond. By: Tahir Bhatti